Publications 2023

Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086

Publications 2022

Tahiri A, Puco K, Naji F, Kristensen VN, Alfsen GC, Farkas L, Nilsen FS, Müller S, Oldenburg J, Geisler J (2022)
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
Oncotarget, 13, 970-981
DOI 10.18632/oncotarget.28257, PubMed 36093296

Publications 2021

Bahrami N, Jabeen S, Tahiri A, Sauer T, Ødegård HP, Geisler SB, Gravdehaug B, Reitsma LC, Selsås K, Kristensen V, Geisler J (2021)
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
Breast Cancer Res Treat, 190 (3), 435-449
DOI 10.1007/s10549-021-06399-x, PubMed 34554372

Publications 2020

Tahiri A, Tekpli X, Satheesh SV, DeWijn R, Lüders T, Bukholm IR, Hurtado A, Geisler J, Kristensen VN (2020)
Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer
Breast Cancer Res Treat, 183 (3), 585-598
DOI 10.1007/s10549-020-05763-7, PubMed 32710281

Publications 2019

Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P (2019)
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer
Cell Rep, 29 (13), 4389-4406.e10
DOI 10.1016/j.celrep.2019.11.085, PubMed 31875548

Publications 2018

Tahiri A, Aure MR, Kristensen VN (2018)
MicroRNA Networks in Breast Cancer Cells
Methods Mol Biol, 1711, 55-81
DOI 10.1007/978-1-4939-7493-1_4, PubMed 29344885

Publications 2017

Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659

Quigley DA, Tahiri A, Lüders T, Riis MH, Balmain A, Børresen-Dale AL, Bukholm I, Kristensen V (2017)
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue
Oncoimmunology, 6 (11), e1356142
DOI 10.1080/2162402X.2017.1356142, PubMed 29147603

Publications 2013

Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN (2013)
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
Carcinogenesis, 35 (1), 76-85
DOI 10.1093/carcin/bgt333, PubMed 24104550

Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J (2013)
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma
PLoS One, 8 (8), e72692
DOI 10.1371/journal.pone.0072692, PubMed 24023633